Progesterone Powder CAS 57-83-0: Why the Same API Requires Different Formulation Strategies

Progesterone Powder CAS 57-83-0 is a steroid pharmaceutical ingredient used in several established dosage-form systems, including oral capsules, oil-based injections, and vaginal formulations. The Fox Bio product page identifies Progesterone Powder CAS 57-83-0 as a white powder with the molecular formula C21H30O2 and a listed purity of 99%.

What makes Progesterone particularly interesting from a formulation perspective is that the same API cannot simply be placed into every dosage form using the same development approach. Progesterone is practically insoluble in water, while commercial dosage forms use very different ways to manage that property. Oral capsules may use micronized progesterone and an oil-containing system, injectable products dissolve progesterone in a suitable vegetable oil, while vaginal inserts depend on a solid excipient matrix.

For formulation development, the important question is therefore not only “Is this Progesterone CAS 57-83-0?” but also “How will this progesterone powder behave in the intended dosage form?”

One Progesterone API, Several Very Different Formulation Problems

Progesterone has the same molecular structure regardless of whether it eventually appears in a capsule, injection, or vaginal insert. What changes is the environment surrounding the API.

This creates very different formulation priorities:

The value of this comparison is that it moves beyond simply listing “applications.” It explains why Progesterone Powder CAS 57-83-0 can require different raw-material considerations depending on what is being developed.

Why Oral Progesterone Capsules Focus on Particle Size

Progesterone is practically insoluble in water, which creates an obvious challenge for oral dosage forms. If the crystalline particles do not disperse and dissolve effectively, simply placing progesterone powder inside a capsule is not enough to create a well-designed formulation.

Current commercial oral progesterone capsules contain micronized progesterone. Official product information also notes that micronization increases the oral bioavailability of progesterone. These capsules combine micronized progesterone with ingredients that include an oil phase and lecithin.

This makes particle characteristics particularly relevant for oral formulation development. Smaller particles provide more surface area, but particle size can also influence how the powder mixes with the carrier and whether the API remains evenly distributed during manufacturing.

For this type of application, useful questions include:

• Is the progesterone supplied in the required particle-size range?
• Can it disperse consistently in the selected formulation system?
• Does the manufacturing process maintain uniform API distribution?
• Are physical properties consistent between batches?

This is why an oral formulation may need more information than chemical purity alone.

Oil-Based Injection Solves the Same Solubility Problem Differently

An injectable progesterone formulation approaches the poor water solubility of progesterone from another direction.

Commercial progesterone injections are formulated as sterile solutions in a suitable vegetable oil, with current products using sesame oil systems. Progesterone remains the same C21H30O2 molecule, but instead of relying primarily on particle-size reduction, the formulation is designed around a non-aqueous vehicle.

Once progesterone is being developed for an oil-based liquid system, the development priorities change. The formulation now needs to consider whether the required progesterone concentration can be maintained in the chosen vehicle and whether the finished solution remains physically stable.

Relevant concerns may include:

• compatibility between progesterone and the selected oil vehicle;
• solution clarity;
• crystallization risk;
• concentration consistency;
• stability of the complete liquid formulation.

This illustrates an important principle: a raw-material property that is critical for one dosage form may become less important than another property in a different dosage form.

Vaginal Inserts Create a Different Challenge Again

Progesterone is also used in vaginal insert formulations. Current approved products demonstrate that progesterone can be incorporated into a solid matrix containing excipients such as lactose monohydrate, povidone, and adipic acid.

Unlike an oil-based injection, the goal is not to create a clear liquid solution. Unlike an oral oil-filled capsule, the dosage-form structure is also different. The API must instead be distributed consistently throughout a solid formulation designed for local administration.

For this type of development, the focus shifts toward properties such as:

• uniform dispersion of progesterone through the formulation;
• compatibility with the excipient system;
• reproducible tablet or insert manufacture;
• physical stability during storage;
• consistent release from the finished dosage form.

The same Progesterone CAS 57-83-0 is present, but the formulation problem has changed completely.

Why Doesn’t High Purity Guarantee Consistent Formulation Performance?

For Progesterone Powder CAS 57-83-0, purity is an important indicator of raw material quality, but it does not, by itself, determine how the material will perform once incorporated into a formulation. This is particularly important for APIs with low water solubility, where the physical properties of the powder can directly influence downstream processing and formulation performance.

Even when two batches have similar purity levels, differences in particle size distribution, crystalline form, moisture content, or dispersibility may lead to variations in mixing, dispersion, and dissolution under the same processing conditions. As a result, two chemically similar batches may not always behave identically during formulation development.

When evaluating whether Progesterone Powder is suitable for a specific dosage form, two aspects should therefore be considered together:

• Chemical Quality: Confirm the identity, assay, and impurity profile of the raw material.
• Physical Performance: Evaluate whether particle size, crystalline form, and dispersion characteristics are suitable for the target formulation and manufacturing process.

For an API such as progesterone, whose formulation behavior can be strongly influenced by its physical characteristics, a single purity value provides only part of the picture. A more meaningful evaluation considers whether the material’s chemical quality and physical properties work together to support consistent processing and reliable formulation development.

Choosing the Relevant Progesterone Properties Starts With the Dosage Form

There is no single progesterone property that deserves the same priority in every application.

For an oral capsule, particle size may be particularly important because dissolution is a major challenge. For an oil-based injection, solubility in the carrier and prevention of crystallization become more relevant. For a vaginal solid dosage form, powder distribution and interaction with the excipient matrix move closer to the center of formulation development.

A practical way to evaluate Progesterone Powder CAS 57-83-0 is therefore to begin with the finished-product concept and work backward.

Instead of asking for every possible specification, identify which raw-material characteristics can directly affect that formulation. Depending on the project, these may include:

• identity and assay;
• related substances;
• particle-size distribution;
• physical appearance;
• moisture;
• crystallinity or solid-state characteristics;
• compatibility with the selected vehicle or excipients.

This creates a more meaningful connection between API data and actual development work.

Progesterone Powder CAS 57-83-0 From Little Fox Bio

Little Fox Bio lists Progesterone Powder CAS 57-83-0 within its API product range. The product is supplied as a white powder with the molecular formula C21H30O2, EINECS number 200-350-6, and listed purity of 99%.

The site also identifies pharmaceutical formulations and scientific research among the product's application directions. For specific formulation projects, product specifications and batch documentation can be evaluated together with the physical-property requirements of the intended dosage form.

Conclusion

Progesterone Powder CAS 57-83-0 provides a useful example of why an API cannot be evaluated independently of its final dosage form.

Oral capsules, oil-based injections, and vaginal inserts can all contain progesterone, but they solve the API's formulation challenges in different ways. Oral development may emphasize particle size and dispersion, injectable development focuses more heavily on the oil vehicle and solution stability, while solid vaginal formulations require consistent distribution within a different excipient system.

The practical value of understanding these differences is straightforward: the right progesterone specification depends partly on what the powder needs to do in the finished formulation.

FAQ

What is Progesterone Powder CAS 57-83-0 used for?

Progesterone is used as an API in established pharmaceutical dosage forms including oral capsules, oil-based injections, and vaginal formulations. Different dosage forms require different formulation strategies.

Why is progesterone difficult to formulate in water-based systems?

Progesterone is practically insoluble in water, so formulation strategies often need to address its limited aqueous solubility through particle engineering, carrier selection, or alternative dosage-form design.

Is 99% purity enough to determine whether progesterone powder suits a formulation?

No. Chemical purity is important, but properties such as particle size, physical form, dispersion, and compatibility with the selected formulation system may also affect development.

Do all progesterone dosage forms require micronized powder?

No. Micronization is particularly relevant to established oral progesterone formulations, while other dosage forms may use different strategies, such as dissolving progesterone in a suitable oil vehicle.